Authors :
Alberto Cundapí Núñez; Gerardo Grajales Yuca; Jesús Miguel Leyva Cervantes; Ana Paola Rubiano Murcia; Marco Antonio Ordoñez Juárez; Jenner Josué Martínez
Volume/Issue :
Volume 5 - 2020, Issue 7 - July
Google Scholar :
http://bitly.ws/9nMw
Scribd :
https://bit.ly/30yw7MH
DOI :
10.38124/IJISRT20JUL252
Abstract :
This document sets out the results of a study
aimed at estimating the therapeutic efficacy of
ivermectin as an adjuvant in the treatment of COVID-19
patients treated at the Specialty Hospital Vida Mejor of
the Institute of Social Security for Workers of the State
of Chiapas, ISSTECH, Mexico. Ivermectin as an
adjuvant in the treatment of COVID-19 patients is more
effective (92%) outpatient patients. In critical
hospitalized and severe hospitalized patients, ivermectin
had a significant impact, both in improving patients'
health and decreasing lethality
Keywords :
Ivermectin, COVID-19, Efficacy.
This document sets out the results of a study
aimed at estimating the therapeutic efficacy of
ivermectin as an adjuvant in the treatment of COVID-19
patients treated at the Specialty Hospital Vida Mejor of
the Institute of Social Security for Workers of the State
of Chiapas, ISSTECH, Mexico. Ivermectin as an
adjuvant in the treatment of COVID-19 patients is more
effective (92%) outpatient patients. In critical
hospitalized and severe hospitalized patients, ivermectin
had a significant impact, both in improving patients'
health and decreasing lethality
Keywords :
Ivermectin, COVID-19, Efficacy.
